Sildenafil: Two decades of benefits or risks?

Aging Male

Volumn 16, Issue 3, 2013, Pages 85-91

  Leoni, Luís Antônio B ^a   Leite, Gerson S ^a   Wichi, Rogério B ^b   Rodrigues, Bruno ^a  

^a SÃO JUDAS TADEU UNIVERSITY   (Brazil)

^b FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

Author keywords

Adverse events; Efficacy; Erectile dysfunction; Safety; Sildenafil

Indexed keywords

FLUOXETINE; SILDENAFIL;

BACKACHE; CARDIOVASCULAR DISEASE; COMORBIDITY; COST BENEFIT ANALYSIS; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; INSOMNIA; MALE; MULTIPLE SCLEROSIS; MYALGIA; PELVIS PAIN SYNDROME; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SLEEP DISORDERED BREATHING; SPINAL CORD INJURY; VISUAL DISORDER;

COMORBIDITY; ERECTILE DYSFUNCTION; HUMANS; MALE; PIPERAZINES; PURINES; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84883571857     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.3109/13685538.2013.801952     Document Type: Review

References (72)

1. NIH Consensus Conference. NIH Consensus Development Panel on Impotence. J Am Med Assoc 1993;270:83-90.
2. Aytaç IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU iIternational 1999;84:50-6.
3. Kendirci M, Nowfar S, Hellstrom WJG, Orleans N. The impact of vascular risk factors on erectile function. Drugs of Today 2005;41: 65-74.
4. Katzenstein L. Viagra-The remarkable story of the discovery and launch. New York: CMD Publishing; 2001.
5. Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. International journal of impotence research 2002;14: 466-71.
6. Guay AT. ED2: erectile dysfunctionendothelial dysfunction. Endocrinology and Metabolism Clinics of North America 2007;36: 453-63.
7. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. New Engl J Med 1996; 334:873-7.
8. Padma-Nathan H, Hellstrom W, Kaiser F, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. New Engl J Med 1997;336:1-7.
9. Corona G, Razzoli E, Forti G, Maggi M. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008;31:799-808.
10. Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafill citrate for the treatment of erectile dysfunction. Br J Clin Pharmacol 2002;53:61S-5S.
11. Montorsi F, Padma-nathan H, Buvat J. Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebocontrolled trial. J Sex Med 2004;1:168-78.
12. Padma-Nathan H, Stecher V, et al. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, doubleblind, placebo-controlled trial. Urology 2003;62:400-3.
13. Sáenz de Tejada I. Vardenafil duration of action. European urology 2006;50:901-2.
14. Shabsigh R, Burnett AL, Eardley I, et al. Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials. BJU International 2005;96:857-63.
15. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78:257-61.
16. Campbell SF. Science, art and drug discovery: a personal perspective. Clinical Science 2000 Oct;99:255-60.
17. Palumbo F, Bettocchi C, Selvaggi FP, et al. Sildenafil: efficacy and safety in daily clinical experience. Eur Urol 2001;40:176-80.
18. Eardley I, Morgan R, Dinsmore W, et al. Efficacy and safety of sildenafil citrate in the treatment of men with mild to moderate erectile dysfunction. Br J Psychiatry 2001 Apr;178:325-30.
19. Meuleman E, Cuzin B, Opsomer RJ, et al. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU International 2001;87:75-81.
20. Montorsi F, Dermott TEDMC, Morgan R, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999;53:1011-18.
21. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338: 1397-404.
22. Christiansen E, Guirguis WR, Cox D, Osterloh IH. Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int J Impot Res 2000 Jun;12:177-82.
23. Benchekroun A, Faik M, Benjelloun S, et al. A baseline-controlled, open-label, flexible dose-escalation study to assess the safety and efficacy of sildenafil citrate (Viagra) in patients with erectile dysfunction. Int J Impot Res 2003;15:S19-24.
24. Fujisawa M, Sawada K. Clinical efficacy and safety of sildenafil in elderly patients with erectile dysfunction. Archives of Andrology 2004;50:255-60.
25. Levinson IP, Khalaf IM, Shaeer KZM, Smart DO. Efficacy and safety of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in Egypt and South Africa. Int J Impot Res 2003;15:S25-9.
26. Gómez F, Davila H, Costa A, et al. Efficacy and safety of oral sildenafil citrate (Viagra) in the treatment of male erectile dysfunction in Colombia, Ecuador, and Venezuela: a double-blind, multicenter, placebo-controlled study. Int J Impot Res 2002;14: S42-7.
27. Becher E, Tejada Noriega A, Gomez R, Decia R. Sildenafil citrate (Viagra 1) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, flexible-dose escalation study. Int J Impot Res. 2002;S2:S33-41.
28. Lim PHC, Ng FC, Cheng CWS, et al. Clinical safety profile of sildenafil in Singaporean men with erectile dysfunction: premarketing experience (ASSESS-I evaluation). The Journal of international medical research 2002;30:137-43.
29. Tan HM, Moh CLC, Mendoza JB, et al. Asian sildenafil efficacy and safety study (assess-1): a double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. Urology 2000;56: 635-40.
30. Chen KK, Hsieh JT, Huang ST, et al. ASSESS-3: a randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan. International journal of impotence research 2001;13: 221-9.
31. Young JM, Bennett C, Gilhooly P, et al. Efficacy and safety of sildenafil citrate (Viagra) in black and hispanic american men. Urology 2002;4295:39-48.
32. Glina S, Bertero E, Claro J, et al. Efficacy and safety of flexibledose oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction in Brazilian and Mexican men. International journal of impotence research 2002;14:S27-32.
33. Choi HK, Ahn TY, Kim JJ, et al. A double-blind, randomisedplacebo, controlled, parallel group, multicentre, flexible-dose escalation study to assess the efficacy and safety of sildenafil administered as required to male outpatients with erectile dysfunction in Korea. International journal of impotence research 2003;15: 80-6.
34. Zonana Farca E, Francolugo-Vélez V, Moy-Eransus C, et al. Selfesteem, confidence and relationship satisfaction in men with erectile dysfunction: a randomized, parallel-group, double-blind, placebo-controlled study of sildenafil in Mexico. Int J Impot Res 2008;20:402-8.
35. Lewis R, Bennett CJ, Borkon WD, et al. Patient and partner satisfaction with viagra (sildenafil citrate) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology 2001;57:960-5.
36. Park HJ, Park NC, Shim HB, et al. An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents. J Sex Med 2008;5:2405-13.
37. Albuquerque DC, Miziara LJ, Saraiva JFK, et al. Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs. Braz J Urol 2005;31:342-53; discussion 354-5.
38. Pickering TG, Shepherd AMM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens 2004;17: 1135-42.
39. Aranda P. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens 2004;17:139-45.
40. Rubio-Aurioles E, Porst H, Eardley I, Goldstein I. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 2006;3: 1037-49.
41. Katz SD, Parker JD, Glasser DB, et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol 2005;95:36-42.
42. Amin A, Mahmoudi E, Navid H, Chitsazan M. Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure? Congestive Heart Failure 2013;19:99-103.
43. Rendell MS. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. J Am Med Assoc 1999;281:421-6.
44. Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. Journal of diabetes and its complications 2004;18:205-10.
45. Price DE, Gingell JC, Gepi-Attee S, et al. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 1998;15:821-5.
46. Escobar-Jiménez F. Efficacy and safety of sildenafil in men with type 2 diabetes mellitus and erectile dysfunction. Med Clin (Barc) 2002;119:121-4.
47. Ergin S, Gunduz B, Ugurlu H, et al. A placebo-controlled, multicenter, randomized, double-blind, flexible-dose, two-way crossover study to evaluate the efficacy and safety of sildenafil in men with traumatic spinal cord injury and erectile dysfunction. Spinal Cord 2008;31:522-31.
48. Giuliano F, Hultling C, El Masry WS, et al. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Ann Neurol 1999;46:15-21.
49. Derry FA, Dinsmore WW, Fraser M, et al. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 1998;51:1629-33.
50. Maytom MC, Derry FA, et al. A two-part pilot study of sildenafil (VIAGRA) in men with erectile dysfunction caused by spinal cord injury. Spinal Cord 1999;37:110-6.
51. Sánchez Ramos A, Vidal J, Jáuregui ML, et al. Efficacy, safety and predictive factors of therapeutic success with sildenafil for erectile dysfunction in patients with different spinal cord injuries. Spinal Cord 2001;39:637-43.
52. Schmid DM, Schurch B, Hauri D. Sildenafil in the treatment of sexual dysfunction in spinal cord-injured male patients. Eur Urol 2000;38:184-93.
53. Vozmedianochicharro R, Solermartinez J, Moralesjimenez P, et al. Estudio prospectivo para valorar el impacto del sildenafilo 50 mg/d?́a durante 28 d́as en pacientes con disfunción eréctil y sintomatolog?́a del tracto urinario inferior secundaria a hiperplasia benigna de próstata. Revista Internacional de Andrología 2008;6: 84-8.
54. Moemen MN, Fahmy I, AbdelAal M, et al. Erectile dysfunction in spinal cord-injured men: different treatment options. Int J Impot Res 2008;20:181-7.
55. Perimenis P, Karkoulias K, Konstantinopoulos A, et al. Sildenafil versus continuous positive airway pressure for erectile dysfunction in men with obstructive sleep apnea: a comparative study of their efficacy and safety and the patient's satisfaction with treatment. Asian J Androl 2007;9:259-64.
56. Perimenis P, Konstantinopoulos A, Karkoulias K, et al. Sildenafil combined with continuous positive airway pressure for treatment of erectile dysfunction in men with obstructive sleep apnea. Int Urol Nephrol 2007;39:547-52.
57. Safarinejad MR. Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study. J Urol 2009; 181:252-8.
58. Fowler CJ. A double blind, randomised sutdy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Am Med Assoc 2005;76:700-5.
59. El-Bahnasawy MS, Ismail T, Elsobky E, et al. Prognostic factors predicting successful response to sildenafil after radical cystoprostatectomy. Scandinavian journal of urology and nephrology 2008; 42:110-5.
60. Weber DC, Bieri S, Kurtz JM, Miralbell R. Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. J Clin Oncol 1999; 17:3444-9.
61. Fava M, Nurnberg HG, Seidman SN, et al. Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry 2006;67: 240-6.
62. Dording CM, LaRocca RA, Hails KA, et al. The effect of sildenafil on quality of life. Ann Clin Psychiatry 2013;25: 3-10.
63. Hussain IF. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371-4.
64. Raffaele R. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol 2002;41:382-6.
65. Mahon A, Sidhu PS, Muir G, Macdougall IC. The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients. Am JKidney Dis 2005;45:381-7.
66. Barrou B, Cuzin B, Malavaud B, et al. Early experience with sildenafil for the treatment of erectile dysfunction in renal transplant recipients. Nephrol Dial Transplant 2003;18:411-7.
67. Seibel I. Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. J Am Soc Nephrol 2002;13:2770-5.
68. Safarinejad MR, Kolahi AA, Ghaedi G. Safety and efficacy of sildenafil citrate in treating erectile dysfunction in patients with combat-related post-traumatic stress disorder: a double-blind, randomized and placebo-controlled study. BJU International 2009;104:376-83.
69. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96:313-21.
70. Bechara A, Casabé A, De Bonis W, et al. Recreational use of phosphodiesterase type 5 inhibitors by healthy young men. J Sex Med 2010;7:3763-42.
71. Fisher DG, Malow R, Rosenberg R, et al. Recreational viagra use and sexual risk among drug abusing men. Am J Infect Dis 2006;2: 107-14.
72. DeBusk R. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol 2004;93:147-53.